medigraphic.com

2019, Number 2

<< Back Next >>

Rev Hematol Mex 2019; 20 (2)

New paradigms in the autologous transplant for treatment of multiple myeloma

Gómez-Morales E

Language: Spanish
References: 36
Page: 106-111
PDF size: 293.04 Kb.


ABSTRACT

Multiple myeloma (MM) is an incurable disease, characterized by abnormal proliferation of plasma cells. In the Mexican guidelines of multiple myeloma, it is estimated that it represents 4-8% of the haematological ailments and 90% occurs in people older than 50 years. Through this review, we will address key points that involve the approach of the patient with multiple myeloma that is a candidate for transplantation, from the clinical perspective to the ethical and financial.


REFERENCES

  1. México- Global cancer Observatory. gco.iarc.fr/today/data/ factsheets/…/484-mexico-fact-sheets.pdf

  2. CENETEC Guia de Práctica Clínica de Diagnóstico y Tratamiento de MM. Mexico. Secretaría de Salud 2010. http//:cenetec.salud.gob.mx/interior/gpc.html.

  3. Alvarado Ibarra M, Alvarez Vera JL, Anaya Cuellar I, De la Peña Celaya A, García Fernandez L, Hernández Ruíz y col. Primer Consenso nacional de Mieloma Múltiple por Hematólogos del ISSSTE. Rev Hematol Mex 2015;16:306-332.

  4. Cid Ruzafa J, Merinopoulou E, Baggaley RF, Leighton P, Werther W, Felici D, et al. Patient population with multiple myeloma and transitions across different lines in the USA: an epidemiologic model. Pharmacoepidemiol Drug Safety 2016;25:871-879.

  5. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Sem Oncol 2016;43:676-681.

  6. Damlaj M, Fakih RE, Hashmi SK. Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. Blood Reviews 2019;33:63-73.

  7. Yanamandra U, Saini N, Chauhan P, Sharma T, Khadwal A, Prakash G, et al. AYA-myeloma: Real world, single center experience over last 5 years. J Adolescent and Young Adult Oncology 2018; https://doi.org/10.1089/jayao.2017.0034

  8. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, et al. Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: effect of age. Clin Lymphoma Myeloma Leukemia 2017;17(3):165-172.

  9. Huang Li-W, Bacon W, Cirrincione C, Peterson B, Long G, Rizzieri D, et al. Efficacy and safety of high dose chemotherapy with autologous stem cell transplantation in seniors versus younger adults with diagnosed multiple myeloma. Hematol. Oncol 2017;35(4):752-759.

  10. Marini C, Maia T, Bergantin R, Pires J, Aguiar E, Guimaräes JE, et al. Real life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Ann Hematol 2019;98:369-379.

  11. Palumbo A, Bringhen S, Mateos MV, Larocca A. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international Myeloma Working Group report. Blood 2015;125:3100-3104.

  12. Birmann BM, Andreotti G, De Roos AJ, Camp NJ, Chiu BCH, Spinelli JJ, et al. Young adult and usual adult body mass index and multiple myeloma risk: A pool analysis in the International Multiple Myeloma Consortium (IMMC). Cancer Epidemiol Biomarkers Prev 2017;26(6):876-85.

  13. González Svatetz CA, Gofay Arnó A. Obesidad y cáncer: “las amistades peligrosas”. Med Clin (Barc) 2015;145(1):24-30.

  14. Masarwi M, DeSchiffart A, Ham J, Reagan MR. Multiple myeloma and fatty acid metabolism. JBMR Plus (WOA) 2019;3(3):E10173. DOI:10.1002/JBM4.10173

  15. Ahn IE, Mailankody S. Controversies in multiple myeloma: Evidence-based update. Sem Oncol 2016;43:666-675.

  16. Mailankody S, Korde N, Lesokhin A, Lendavai N, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015;12286-12295.

  17. Paiva B, van Dongen JJM, Orfao A. New criteria for response assessment: role of a minimal residual disease in multiple myeloma. Blood 2015;125(20):3059-3068.

  18. Oriol A, Motlló C. Nuevos fármacos en el tratamiento del mieloma múltiple. Med Clin (Barc) 2014;143(6):268-274.

  19. Sekine L, Klarmann-Ziegelmann P, Manica D, daFonte Pithan C, Sosnoski M, Daudt Morais V, et al. Frontline treatment for transplant eligible multiple myeloma: A 6474 patients network meta analysis. Hematol Oncol 2019;37:62-74.

  20. Garcia Quetglas E, Aranza Perea JR, Lecumberri Viallamediana R. Nuevas estrategias terapéuticas en el tratamiento del mieloma múltiple. Análisis de su eficacia y coste-efectividad. Med Clin (Barc) 2008;130(16):626-635.

  21. Braunstein M, Niesvizky R. Deferring autologous stem cell transplantation for consolidation on minimal residual disease in multiple myeloma. Sem Oncol 2016;43:709-711.

  22. Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Myeloma in the real world: What is really happening? Clin Lymphoma Myeloma & Leukemia 2016;17(3):133-144.

  23. Puyade M, Defossez G, Guilhot F, Leleu X, Ingrand P. Age-related health care disparities in multiple myeloma. Hematol Oncol 2018;36:224-231.

  24. Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, et al. Management of infectious complications in multiple myeloma patients: Expert panel consensus based recommendations. Bloods Rev 2019;34:84-94.

  25. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, et al. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network. Leukemia 2017, 18 de diciembre: doi:10.1038/leu.2017.353.

  26. Torrent A, Ferrá C, Morgades M, Jimenez MJ, Sancho JM Vives S y col. Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. Med Clin (Barc) 2018;150(11):421-427.

  27. Fojo T. The high cost of ignorance in oncology. Sem Oncol 2016;43:623-624.

  28. Allen PB, Flowers CR. Balancing patient value and payer cost in hematologic malignancies: can it be done? Expert Rev Pharmacoeconomic Outcome Res 2018;18(2):123-126.

  29. Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States and what are the solutions? Mayo Clin Proc 2015;90(4):500-5004.

  30. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, et al. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Hematol 2017;99:532-535.

  31. Lahuerta JJ, Martínez-López J, Grande C, Bladé J, de la Serna J, Alegres A, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000;109:138-147.

  32. Bashir Q, Tall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous hematopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Hematol 2019, 03; https:// doi.org/10.1016/S2352-3026(19)30023-7

  33. Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, et al. Hematopoietic progenitor cell mobilization with “just in time” plerixafor approach is a cost effective alternative to routine plerixafor use. Cytotherapy 2015;17(12):1785-1792.

  34. Afifi S, Adel NG, Devlin S, Duck E, Vanak J, Landau H, Chung DJ, et al. Upfront plerixafor plus GCSF versus cyclophosphamide plus GCSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplant 2016;51:546-552.

  35. Lopez Otero A, Ruíz Delgado G, Ruiz Argüelles G. ¿Es cierto que el trasplante de médula ósea autólogo mejora el pronóstico de pacientes de los pacientes con mieloma múltiple? Expericneia de una sola institución en México. Medicina Universitaria 2008;10:187-189.

  36. Vela-Ojeda J, García Ruíz-Esparza MA. Trasplante de células hematopoyéticas en mieloma múltiple. Rev Invest Clin 2015;57(2):305-313.




2020     |     www.medigraphic.com